Skip to main content
Premium Trial:

Request an Annual Quote

Cubist Buys Minority Stake in Novalon; Will Provide Bioinformatics


CAMBRIDGE, Mass.--Cubist Pharmaceutical Inc. here has taken a $1 million minority position in Novalon Pharmaceutical Corp. and will provide the Chapel Hill, N.C., startup with research support, including bioinformatics help. Cubist also gained a six-month option to acquire all outstanding shares of Novalon. An internet search led to the match.

The companies will collaborate in pursuit of antibacterial and antifungal drug leads. "They've got the screening and genomics expertise. We're sitting in the middle with our technology pulling all this together," commented Novalon CEO Dana Fowlkes.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.